Thus, our assay system can demonstrate the cytoprotective effects of a known tau aggregation inhibitor and a microtubule stabilizer, suggesting that this assay provides a platform for identifying novel neurodegenerative disease therapeutics. The gene discussed is MAPT; the disease is neurodegenerative disease.